US 12,220,457 B2
Modified CMV gB protein and CMV vaccine including same
Masaharu Torikai, Kumamoto (JP); Hiroaki Mori, Kumamoto (JP); Tomohiro Nishimura, Kumamoto (JP); Miyuki Matsumoto, Kumamoto (JP); Hiroyuki Shimizu, Saitama (JP); Akihiro Koube, Kumamoto (JP); Takamasa Nagatomo, Kumamoto (JP); and Naoki Inoue, Gifu (JP)
Assigned to KM Biologics Co., Ltd., Kumamoto (JP)
Appl. No. 17/285,874
Filed by KM Biologics Co., Ltd., Kumamoto (JP)
PCT Filed Oct. 24, 2019, PCT No. PCT/JP2019/041784
§ 371(c)(1), (2) Date Apr. 15, 2021,
PCT Pub. No. WO2020/085457, PCT Pub. Date Apr. 30, 2020.
Claims priority of application No. 2018-201201 (JP), filed on Oct. 25, 2018.
Prior Publication US 2021/0346494 A1, Nov. 11, 2021
Int. Cl. A61K 39/25 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/25 (2013.01) [C12N 7/00 (2013.01); C12N 2710/16134 (2013.01)] 6 Claims
 
1. A modified CMV gB protein comprising a head region modified from a head region in an envelope glycoprotein B (CMV gB protein) in a wild type cytomegalovirus and having an improved ability to induce body region-recognizing antibodies, wherein the modification in the head region comprises modification by sugar chain introductions to at least 2 amino acid residues selected from the group consisting of amino acid residues at corresponding positions to the positions 77, 544. 588, and 609 in the amino acid sequence set forth in SEQ ID NO: 1.